MINT-FENOFIBRATE E TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
23-06-2017
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
FENOFIBRATE
Beschikbaar vanaf:
MINT PHARMACEUTICALS INC
ATC-code:
C10AB05
INN (Algemene Internationale Benaming):
FENOFIBRATE
Dosering:
145MG
farmaceutische vorm:
TABLET
Samenstelling:
FENOFIBRATE 145MG
Toedieningsweg:
ORAL
Eenheden in pakket:
90
Prescription-type:
Prescription
Therapeutisch gebied:
FRIBIC ACID DERIVATIVES
Product samenvatting:
Active ingredient group (AIG) number: 0118895006; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2020-04-28
Productkenmerken
PRODUCT MONOGRAPH
Pr
MINT-FENOFIBRATE E
fenofibrate
film-coated tablets (145 mg)
USP
LIPID METABOLISM REGU
LATOR
Mint Pharmaceuticals Inc.
Date of Preparation:
1093 Meyerside Dr., Unit #1
JUNE 15, 2017
Mississauga, Ontario
L5T 1J6
Submission Control No: 186636
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT
INFORMATION.........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
..................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
14
DOSAGE AND ADMINISTRATION
..............................................................................
18
OVERDOSAGE
.................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 19
STORAGE AND STABILITY
..........................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 21
PART II: SCIENTIFIC INFORMATION
........................................................................
23
PHARMACEUTICAL INFORMATION
..........................................................................
23
CLINICAL TRIALS
..........................................................................................................
24
DETAILED PHARMACOLOGY
.....................................................................................
29
TO
Lees het volledige document
